Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,583,530.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $587.74, for a total value of $5,583,530.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at $190,688,128.82. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Down 0.6%

UTHR traded down $3.78 during trading on Tuesday, reaching $584.10. The company had a trading volume of 407,358 shares, compared to its average volume of 553,351. The stock has a market cap of $24.88 billion, a P/E ratio of 22.04, a PEG ratio of 3.94 and a beta of 0.49. The business has a 50 day simple moving average of $544.61 and a 200-day simple moving average of $536.98. United Therapeutics Corporation has a 52 week low of $455.63 and a 52 week high of $614.23.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. During the same quarter last year, the firm earned $7.16 EPS. The company’s revenue was up 4.1% on a year-over-year basis. As a group, equities research analysts expect that United Therapeutics Corporation will post 25.08 EPS for the current fiscal year.

United Therapeutics declared that its board has approved a share repurchase program on Thursday, October 22nd that permits the company to repurchase $2 billion in shares. This buyback authorization permits the biotechnology company to reacquire up to 8.3% of its stock through open market purchases. Share buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of recent analyst reports. BTIG Research increased their price objective on shares of United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research report on Wednesday, October 28th. Cantor Fitzgerald restated an “overweight” rating and set a $850.00 target price on shares of United Therapeutics in a research report on Monday, October 26th. Weiss Ratings cut United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Finally, Raymond James Financial set a $720.00 price target on United Therapeutics in a report on Wednesday, November 4th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $676.40.

Get Our Latest Stock Analysis on UTHR

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in UTHR. Toth Financial Advisory Corp lifted its holdings in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares in the last quarter. Fiduciary Financial Advisors bought a new position in United Therapeutics in the 2nd quarter worth about $30,000. Gen Wealth Partners Inc bought a new position in United Therapeutics in the 3rd quarter worth about $34,000. Caitlin John LLC purchased a new position in shares of United Therapeutics during the second quarter worth approximately $37,000. Finally, PFS Partners LLC purchased a new position in shares of United Therapeutics during the third quarter worth approximately $45,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Featured Articles

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.